Lacosamide monotherapy for the treatment of childhood epilepsy with centrotemporal spikes.

Autor: Okanishi T; Division of Child Neurology, Department of Brain and Neurosciences, Faculty of Medicine, Tottori University, Yonago, Japan; Comprehensive Epilepsy Center, Seirei Hamamatsu General Hospital Hamamatsu, Japan. Electronic address: t.okanishi@tottori-u.ac.jp., Fujii Y; Department of Pediatrics, Hiroshima City Funairi Citizens Hospital, Hiroshima, Japan., Sakuma S; Department of Pediatrics, Osaka City University Graduate School of Medicine, Osaka, Japan., Shiraishi H; Department of Pediatrics, Hokkaido University Hospital, Sapporo, Japan., Motoi H; Department of Pediatrics, Yokohama City University Medical Center, Yokohama, Japan., Yazaki K; Department of Pediatrics, Osaka City University Graduate School of Medicine, Osaka, Japan., Enoki H; Comprehensive Epilepsy Center, Seirei Hamamatsu General Hospital Hamamatsu, Japan., Fujimoto A; Comprehensive Epilepsy Center, Seirei Hamamatsu General Hospital Hamamatsu, Japan.
Jazyk: angličtina
Zdroj: Brain & development [Brain Dev] 2022 Jun; Vol. 44 (6), pp. 380-385. Date of Electronic Publication: 2022 Feb 28.
DOI: 10.1016/j.braindev.2022.02.005
Abstrakt: Objective: Childhood epilepsy with centrotemporal spikes (CECTS) is known as age-limited focal epilepsy syndrome in childhood. Lacosamide is a third-generation antiepileptic drug. This study aimed to evaluate the efficacy of lacosamide monotherapy for the treatment of CECTS.
Methods: We enrolled 18 patients (6 girls and 12 boys) who met the following criteria: 1) the age of onset of the seizures was between 3 and 13 years of age; 2) showing at least hemifacial and/or oropharyngeal seizures; 3) interictal discharges in central and/or middle temporal electrodes; 4) no intellectual disability; 5) treatment duration of lacosamide monotherapy over 6 months. We retrospectively collected and analyzed clinical data and treatment information. We evaluated the seizure occurrences during 0-3, 4-6, and 7-12 months from the treatment initiation and the last 6 months of the follow-up. We also evaluated the outcomes as seizure-free if the patients developed no seizures both over 6 months and 3 times of pretreatment mean seizure interval at the last follow-up.
Results: Of the patients, 39%, 67% and 72% were seizure-free during 0-3, 4-6, and 7-12 months from treatment initiation, respectively. Finally, 83% of the patients achieved seizure freedom. Seizure freedom was achieved in 72% during the first 4 months of treatment. All patients continued lacosamide monotherapy during the study, although four patients showed transient fatigue or somnolence.
Conclusions: Lacosamide showed good efficacy for controlling seizures with fewer adverse effects, and therefore may be a good candidate as a first-line medication for the treatment of new-onset CECTS.
(Copyright © 2022 The Japanese Society of Child Neurology. Published by Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: